专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005046688A3 METHODS OF USE OF THROMBIN RECEPTOR ANTAGONISTS 审中-公开
标题翻译：使用硫蛋白受体拮抗剂的方法
公开(公告)号：WO2005046688A3
公开(公告)日：2005-09-29
申请号：PCT/US2004037519
申请日：2004-11-09
申请人： SCHERING CORP , CHACKALAMANNIL SAMUEL , CLASBY MARTIN C , GREENLEE WILLIAM J , WANG YUGUANG , XIA YAN , VELTRI ENRICO P , CHELLIAH MARIAPPAN V , WU WENXUE , GRAZIANO MICHAEL P , KOSOGLOU TEDDY , CHINTALA MADHU
发明人： CHACKALAMANNIL SAMUEL , CLASBY MARTIN C , GREENLEE WILLIAM J , WANG YUGUANG , XIA YAN , VELTRI ENRICO P , CHELLIAH MARIAPPAN V , WU WENXUE , GRAZIANO MICHAEL P , KOSOGLOU TEDDY , CHINTALA MADHU
IPC分类号： A61K31/343 , A61K31/4525 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D521/00 , A61P9/00 , A61P11/00 , A61P13/12 , A61P25/28 , A61P29/00 , A61P35/00
CPC分类号： A61K31/4525 , A61K31/343 , C07D231/12 , C07D233/56 , C07D249/08 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14
摘要： A method of treating a therapeutic condition comprising administering to a mammal in need of such treatment an effective amount of at least one compound of the formulas (I) and (II) or a pharmaceutically acceptable isomer, salt, solvate or co-crystal form thereof, wherein the substituents are as defined in the specification, wherein said therapeutic condition is a cardiovascular or circulatory disease or condition, an inflammatory disease or condition, a respiratory tract or disease or condition, cancer, acute renal failure, astrogliosis, a fibrotic disorder of the liver, kidney, lung or intestinal tract, Alzheimer's disease, diabetes, diabetic neuropathy, rheumatoid arthritis, neurodegenerative disease, neurotoxic disease, systemic lupus erythematosus, multiple sclerosis, osteoporosis, glaucoma, macular degeneration, psoriasis, radiation fibrosis, endothelial dysfunction, a wound or a spinal cord injury, or a symptom or result thereof. Combination therapy with other therapeutically effective agents is also disclosed.
摘要翻译：治疗治疗条件的方法包括向需要这种治疗的哺乳动物施用有效量的至少一种式（I）和（II）化合物或其药学上可接受的异构体，盐，溶剂合物或共晶体形式其中所述取代基如说明书中所定义，其中所述治疗条件是心血管或循环系统疾病或病症，炎性疾病或病症，呼吸道或疾病或病症，癌症，急性肾功能衰竭，星形胶质细胞增生症，纤维化疾病肝，肾，肺或肠道，阿尔茨海默病，糖尿病，糖尿病性神经病，类风湿性关节炎，神经变性疾病，神经毒性疾病，系统性红斑狼疮，多发性硬化症，骨质疏松症，青光眼，黄斑变性，牛皮癣，放射纤维化，内皮功能障碍伤口或脊髓损伤，或其症状或结果。还公开了与其它治疗有效药物的联合治疗。

2. 发明申请

WO2007084450A3 CANNIBINOID RECEPTOR MODULATORS 审中-公开
标题翻译： CANNIBINOID接收器调制器
公开(公告)号：WO2007084450A3
公开(公告)日：2007-11-08
申请号：PCT/US2007001024
申请日：2007-01-16
申请人： SCHERING CORP , CHACKALAMANNIL SAMUEL , CHELLIAH MARIAPPAN V , CLASBY MARTIN C , EAGEN KEITH A , SCOTT JACK D , WANG YUGUANG , XIA YAN , GREENLEE WILLIAM J
发明人： CHACKALAMANNIL SAMUEL , CHELLIAH MARIAPPAN V , CLASBY MARTIN C , EAGEN KEITH A , SCOTT JACK D , WANG YUGUANG , XIA YAN , GREENLEE WILLIAM J
IPC分类号： C07D209/44 , C07C233/05 , C07C233/59 , C07D209/46 , C07D209/52 , C07D211/58 , C07D307/83 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/10
CPC分类号： C07D209/46 , C07C233/31 , C07C233/58 , C07C233/59 , C07C233/60 , C07C233/90 , C07D209/44 , C07D209/52 , C07D211/58 , C07D307/83 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/10
摘要： A compound having the general structure of Formula (I): Chemical formula should be inserted here as it appears on the abstract in paper form. or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.
摘要翻译：具有式（I）通式结构的化合物：化学式应插入此处，如出现在摘要中的纸张形式。或其药学上可接受的盐，溶剂化物或酯可用于治疗诸如肥胖症，代谢紊乱，成瘾，中枢神经系统疾病，心血管疾病，呼吸系统疾病和胃肠疾病的疾病，病症或病症。

3. 发明申请

WO2007075809A2 OXAZOLOISOQUINOLINE DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS 审中-公开
标题翻译：氧杂氮杂环丁酮衍生物作为硫蛋白受体拮抗剂
公开(公告)号：WO2007075809A2
公开(公告)日：2007-07-05
申请号：PCT/US2006048646
申请日：2006-12-20
申请人： SCHERING CORP , CHACKALAMANNIL SAMUEL , WANG YUGUANG
发明人： CHACKALAMANNIL SAMUEL , WANG YUGUANG
CPC分类号： C07D487/04 , C07D471/04
摘要： Heterocyclic-substituted bi or tricyclics of the formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：式（I）的杂环取代的二环或三环或所述化合物，异构体或外消旋混合物的药学上可接受的盐或溶剂合物，其中代表任选的双键，虚线任选是键或无键，得到双键或单价键，如价格要求所允许的，其中An，Mn，Un，Gn，Jn，Kn，R9，R10，R11，R32，R33，B和Het在本文中定义，其余取代基如说明书以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。还要求与其它心血管药物联合治疗。

4. 发明申请

WO2008060372A3 THROMBIN RECEPTOR ANTAGONISTS BASED ON THE MODIFIED TRICYCLIC UNIT OF HIMBACINE 审中-公开
标题翻译：基于改性三聚体单元的血红蛋白受体拮抗剂
公开(公告)号：WO2008060372A3
公开(公告)日：2008-12-24
申请号：PCT/US2007021259
申请日：2007-10-02
申请人： SCHERING CORP , CHACKALAMANNIL SAMUEL , WANG YUGUANG , THIRUVENGADAM TIRUVETTIPURAM K , ZAVIALOV ILIA A , LI TAO
发明人： CHACKALAMANNIL SAMUEL , WANG YUGUANG , THIRUVENGADAM TIRUVETTIPURAM K , ZAVIALOV ILIA A , LI TAO
IPC分类号： C07D405/06 , A61K31/443 , A61P9/00 , A61P11/00 , A61P25/00 , A61P29/00 , A61P35/00
CPC分类号： C07D405/06
摘要： Multiple stereoisomers of the heterocyclic-substituted tricyclics of the formula: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：公开了下式结构式中R和立体化学结构式所示的化合物或其药学上可接受的盐，溶剂化物或酯的立体异构体：以及含有它们的药物组合物和方法通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病。还要求与其它心血管药物联合治疗。

5. 发明申请

WO2007123949A2 CANNABINOID RECEPTOR MODULATORS 审中-公开
标题翻译： CANNABINOID受体调节剂
公开(公告)号：WO2007123949A2
公开(公告)日：2007-11-01
申请号：PCT/US2007009473
申请日：2007-04-18
申请人： SCHERING CORP , WANG YUGUANG , CHACKALAMANNIL SAMUEL , ROOT YURIKO Y
发明人： WANG YUGUANG , CHACKALAMANNIL SAMUEL , ROOT YURIKO Y
IPC分类号： C07C43/225 , C07C255/54 , C07C255/58
CPC分类号： A61K31/03 , A61K31/10 , C07C43/225 , C07C255/54 , C07C255/58 , C07C2601/08
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable salts or solvates thereof, wherein: Ar 1 is a chlorophenyl group, Ar 2 is a dichlorophenyl group, R 1 is a -(CH 2 )m-X-(CH 2 )n-R 2 group, X is a -NH-, -O-, -C(O)- or -S(O) 2 - group, and R 2 is a substituted phenyl group. These compounds are CB1 receptor modulators. Also disclosed are methods of treating CB1 modulated diseases or conditions such as the metabolic syndrome.
摘要翻译：公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中：Ar 1是氯苯基，Ar 2是二氯苯基， 1是 - （CH 2）2 mX-（CH 2）nR 2 O 2基团，X是-NH-， -O - ， - C（O） - 或-S（O）2 - 基，R 2是取代的苯基。这些化合物是CB1受体调节剂。还公开了治疗CB1调节的疾病或诸如代谢综合征的病症的方法。

6. 发明申请

WO9805292A3 MUSCARINIC ANTAGONISTS 审中-公开
标题翻译：心理拮抗剂
公开(公告)号：WO9805292A3
公开(公告)日：1998-04-02
申请号：PCT/US9713383
申请日：1997-08-06
申请人： SCHERING CORP
发明人： LOWE DEREK B , CHANG WEI K , KOZLOWSKI JOSEPH A , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , WANG YUGUANG , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE D , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS , BOYLE CRAIG D , JOSIEN HUBERT B
IPC分类号： C07D211/58 , A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , A61K
CPC分类号： C07D405/14 , C07C2601/14 , C07D211/24 , C07D211/32 , C07D239/34 , C07D257/04 , C07D295/03 , C07D295/088 , C07D295/092 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D405/12 , C07D409/14
摘要： Di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R?1, R2, R3, R4, R21, R27, R28¿, X, Y and Z as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
摘要翻译：根据式I的二-N-取代哌嗪或1,4-二取代哌嗪化合物（包括所有异构体，盐，酯和溶剂合物），其中R，R 1，R 2，R 3，R 4，R 21，R 27，R 28，X Y和Z如本文所定义的是可用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。还公开了药物组合物和制备方法。还公开了上式化合物与乙酰胆碱酯酶抑制剂的协同组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式